ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Maren Kühr contributed 216 entries already.
Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.
Dr Sonya Montgomery joined OSE Immunotherapeutics SA, based in Nantes, France, as Chief Development Officer.
Cambridge-based biotechnology company Nuclera has appointed William J. Kullback to its board of directors as a non-executive director.
Kufstein-based Single Use Support appointed Darren Verlenden as CEO and strengthens leadership team.
Matt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.
The French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.
The study of G protein-coupled receptor (GPCR) signalling is crucial for understanding a wide range of physiological processes. Among the methods used to monitor calcium signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.
French Innate Pharma SA announced the appointment of Jonathan Dickinson as the Company’s newChief Executive Officer (CEO) and Chairman of the Executive Board. He succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.
AATec Medical was founded in 2022 and is located in the Innovation and Start-up Centre IZB in Planegg-Martinsried.
The volume of samples and drug products requiring -80°C storage continues to increase, and shows no sign of slowing down. For many organisations, meeting these growing ULT storage requirements is challenging. The sheer volume of samples necessitates extensive storage capacity, which demands significant space, substantial energy use, and intensive management. Centralising and automating sample storage can provide a comprehensive solution.